Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Nautilus Biotechnology Secures Up to $125 Million in Common Stock Sales Agreement
PUBLIC · NAUTSep 11, 2026•1 day ago
Amount Raised
$125 Million
Round Type
Post-IPO Equity
San FranciscoOtherBiotechnologyHealth CareLife Science
Investors
Td Securities (Usa), Llc
Description
On September 11, 2026, Nautilus Biotechnology, Inc. entered into a Sales Agreement with TD Securities (USA), LLC to sell shares of the Company’s common stock. This agreement allows for aggregate sales proceeds of up to $125 million through an 'at the market' offering program. TD Cowen will act as the sales agent for these transactions
Company Information
Company
Nautilus Biotechnology
Location
San Francisco, California, United States
About
Nautilus Biotechnology, Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine.
Don't miss Nautilus Biotechnology's next move
Get an email the moment Nautilus Biotechnology raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
5 contacts
Verified contacts12 people are listed at Nautilus Biotechnology. We don't have their email yet.
Predictive Intelligence
Strategic
ML-powered predictions for Nautilus Biotechnology's next move
San FranciscoOtherBiotechnologyHealth CareLife Science